



Will the hydrogen therapy be approved shortly?

Shigeo Ohta

Department of Neurology Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Correspondence to: Shigeo Ohta. Juntendo University Graduate School of Medicine. Department of Neurology Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Email: ohta@nms.ac.jp.

Provenance and Peer Review: This article was commissioned by the Editorial Office, *Annals of Translational Medicine*. The article did not undergo external peer review.

Comment on: Malý O, Zajak J, Hyšpler R, *et al.* Inhalation of molecular hydrogen prevents ischemia-reperfusion liver damage during major liver resection. *Ann Transl Med* 2019;7:774.

Submitted Feb 04, 2020. Accepted for publication Feb 29, 2020.

doi: 10.21037/atm.2020.03.70

View this article at: <http://dx.doi.org/10.21037/atm.2020.03.70>

Ischemia-reperfusion injury is a critical issue in surgical fields

Ischemia-reperfusion is characterized by a restriction of blood supply to multiple organs, followed by the subsequent reperfusion with accompanying re-oxygenation. Ischemia-reperfusion injury causes serious damages in a wide range of conditions by inducing strong oxidative stress. For example, cardiac or cerebral infarction, cardiac arrest, organ translocation, and liver resection cause ischemia-reperfusion injury in multiple organs when blood flow is recovered (1). Because most surgical treatments are associated with ischemia-reperfusion injury, to overcome this damage is one of critical issues in surgery.

Recently, Malý *et al.* reported that inhalation of hydrogen gas (H_2 as the chemical formula or molecular hydrogen) prevented ischemia-reperfusion liver damage during major liver resection using 12 domestic pigs. H_2 treatment reduced oxidative stress, resulting in the mitigation of damages caused by ischemia-reperfusion (2). Because liver resection is one of the high-risk surgeries that often cause fatal complications, H_2 inhalation is awaiting approval as a possible actual therapy.

Hydrogen has emerged as a safe medical gas

Biological effects by several medical gases are experimentally accepted in preventive and therapeutic interventions. Carbon monoxide (CO), hydrogen sulfide (H_2S), and nitric oxide ($\cdot NO$) play important roles as signaling molecules at lower levels; however, they are highly toxic molecules at

higher concentrations. In contrast, H_2 is advantageous in having no cytotoxicity (3).

H_2 was considered as a non-functional and inert gas at body temperature in mammalian cells for a long time. In fact, in the absence of catalysts, H_2 does not react with any biological compounds, including the oxygen molecule, at body temperature. On the other hand, in some bacteria, H_2 can be metabolized by a kind of enzymes termed hydrogenase. In contrast, mammals do not have any functional hydrogenase genes. Thus, this is why H_2 was believed to be non-functional in our cells.

This concept was overturned by a publication in 2007 describing that H_2 acted as a preventive and therapeutic antioxidant through reducing highly reactive oxidants such as hydroxyl radical ($\cdot OH$) and peroxynitrite ($ONOO^-$) in cultured cells, and moreover that H_2 exhibited cytoprotective effects against strong oxidative stress in a model animal (4). Subsequently, a large number of studies have revealed the preventive and therapeutic effects of H_2 . These publications exhibited efficient beneficial effects against oxidative stress in most organs (3). Moreover, it has been revealed that H_2 has multiple functions, including anti-inflammatory, anti-allergic, and anti-apoptotic effects, and regulation of autophagy in most tissues of model animals (3). In turn, H_2 stimulates energy metabolism (5).

H_2 has great advantages because of no or little toxicity (6): H_2 has experimentally no cytotoxicity even at high concentrations (3,7). Importantly for an actual application, the biological safety of H_2 was revealed by the inhalation of an extremely high concentration of H_2

gas in an exotic breathing gas mixture, Hydreliox, which is composed of 49% H₂, 50% helium and 1% O₂. This mixed gas is used to prevent decompression sickness and nitrogen narcosis during deep diving (7). Inhalation of H₂ gas of the range between 1–4% exhibits excellent efficacy (4,8), and there is no risk of fire or explosion when the H₂ concentration is less than 4%.

Molecular hydrogen can be ingested by various ways

There are various methods to ingest H₂ into the body. Inhalation of H₂ gas is a straightforward therapeutic method through a ventilator circuit, facemask, or nasal cannula. Because inhaled H₂ gas defuses rapidly and is incorporated into the whole body, the inhalation is considered as the most suitable method against acute oxidative stress.

H₂ is dissolved in water up to 0.8 mM (1.6 mg/L) at atmospheric pressure and room temperature and does not change pH. Solubilized H₂ (H₂ infused in water; termed H₂-water) may be convenient in potable, and can be administered by a safe way by drinking H₂-water (5).

Alternatively, H₂ can be injected intravenously or intraperitoneally as H₂-saline (H₂ dissolved in saline). This method allows more delivery of H₂ with great efficacy than drinking H₂-water (9). Additionally, H₂-loaded eye drop is applicable by dissolving H₂ in saline and by directly administering to the ocular surface (10).

During cold preservation, H₂ can be delivered to cardiac grafts using an H₂-infused water bath, and efficiently mitigated myocardial injury caused by cold ischemia-reperfusion. This device to saturate organs with H₂ during cold storage may have a merit for actual therapeutic and preventative uses during transplantation (11).

Molecular hydrogen exhibits great efficacy against ischemia-reperfusion injury

Because ischemia-reperfusion induces strong oxidative stress, to overcome the ischemia-reperfusion injuries should be one of the serious issues in many clinical treatments. As an acute rat model, oxidative stress damage was induced by the focal brain infarction followed by reperfusion. The inhalation of H₂ gas markedly mitigated the brain damage by decreasing oxidative stress. Thus, H₂ may be applicable as an effective antioxidant therapy. By the ability to rapidly diffuse across membranes and the blood brain barrier, H₂ can reach any regions in any cells, and react with cytotoxic

reactive oxygen species. Thus, H₂ is considered to protect cells against oxidative damage.

Subsequently, inhalation of H₂ gas improved ischemia-reperfusion injuries in myocardial infarction (8,12). H₂-saline protected against renal ischemia-reperfusion injury. H₂ gas inhalation exhibited great improvement in survival and the neurological deficit score in a rat model with post cardiac arrest syndrome (13). H₂ also mitigated damage during the transplantation of various organs by inhalation (14).

For translational research, the efficacies of H₂ should be examined using large laboratory animals. In dogs, H₂ exerted cardioprotection through the involvements of ATP-dependent K⁺-channels and permeability transition pores of mitochondria (12). In swines, H₂ gas inhalation, perioperatively, diminishes neurologic injury following experimental circulatory arrest (15). A recent publication demonstrated the reduction of oxidative stress induced by ischemia-reperfusion in resection of the liver using domestic pigs (2).

Pilot clinical studies have been performed in cerebral infarction, cardiac infarction and cardiac arrest syndrome (16-18).

Twenty-five patients with acute cerebral infarction inhaled H₂ gas with no significant adverse effects, and were improved in oxygen saturation in comparison with 25 blinded control patients. The H₂ gas therapy significantly improved the relative signal intensity of magnetic resonance imaging in the severe infarction site. NIH Stroke Score was used to evaluate the clinically quantifying stroke severity, and the Barthel Index was used for physical therapy evaluation. These scores were significantly improved by H₂ inhalation in comparison with the control group. These results suggested a potential for widespread and general application of H₂ gas (16).

A prospective, open-label clinical pilot study was designed for 20 patients experiencing ST-elevated myocardial infarction. H₂ inhalation during percutaneous coronary intervention was safe and feasible, and promoted left ventricular reverse remodeling at 6 months after ST-elevated myocardial infarction (17). Five patients with post-cardiac arrest syndrome underwent H₂ gas therapy with accompanying target temperature management. No adverse effects attributable to H₂ inhalation were observed, and 4 patients survived at least 90 days with favorable neurological outcomes (18).

The Japanese Minister of Health, Labour and Welfare received H₂ inhalation therapy as an advanced therapy B for post-cardiac arrest syndrome. This advanced therapy B

is expected to receive approval for the actual application of H₂ therapy. The study protocol for a randomized controlled trial was published as “Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During post-cardiac arrest care (HYBRID II trial)” (19).

Molecular mechanism to exert multiple functions including anti-oxidative stress against ischemia-reperfusion

In the latest knowledge, H₂ can react with only the molecules having extremely oxidative reactivity including ·OH and ONOO⁻ in the absence of a catalyst in biological conditions. According to the reaction rate of H₂ with ·OH, which was obtained in homogeneous aqueous solution, it may be difficult for H₂ to overcome competition with other cellular anti-oxidants; however, the living cell structure is complicated with various microenvironments. The conventional kinetics obtained in homogeneous aqueous conditions cannot be applied to consider the molecular mechanism of H₂.

Experimentally, H₂ decreased the level of cellular ·OH and the subsequent production of lipid peroxides because ·OH triggers a lipid free-radical chain reaction, resulting in the accumulation of lipid peroxides (20).

Severe lipid peroxidation initiates ferroptosis, which was emerged as a new type of cell death, and characterized by condensed mitochondrial membrane densities as well as the diminished amounts or loss of mitochondria crista and outer membrane rupture. Thus, H₂ may protect cells against cell death, such as ferroptosis, in ischemia-reperfusion.

Lipid peroxides are non-enzymatically resolved into end products, some of which function as signal mediators, such as 4-hydroxynonenal (HNE). In turn, HNE modulates Akt/FoxO1 signaling. Because H₂ decreases the level of lipid peroxides, H₂ indirectly may modulate the Akt/FoxO1 signaling pathway (21).

Alternatively, to exert multiple functions in addition to anti-oxidative function, H₂ can regulate various signal transduction pathways and the expression of various genes. As a mechanism, H₂ interferes in the lipid free-radical chain reaction and modifies lipid mediators that function as antagonists of various receptors to modulate signal transduction. For example, a modified oxidized phospholipid suppresses a Ca²⁺ channel, and subsequently inactivates the Ca²⁺-dependent transcription factor NFAT. Because NFAT transcribes several inflammatory

cytokines, including TNF-α and IL-6. In fact, after 2 hours of ischemia-reperfusion, H₂ suppressed the increase in inflammatory cytokines to calm inflammation (13).

Hydrogen therapy may be useful in the treatment of advanced cancers

H₂ was first reported as a ·OH scavenger in 2007, and subsequently the beneficial effects of H₂ were reported in more than 170 disease models and 70 human diseases including ischemia-reperfusion injury, inflammation, metabolic syndrome, and cancer (3).

Recent studies have investigated the application of H₂ gas therapy for patients with advanced cancer.

In Japan, patients with stage IV colorectal cancer inhaled H₂ gas for 3 h/day in their own homes and received chemotherapy. H₂ gas improved progression-free survival and overall survival times, accompanied by a decrease in the abundance of exhausted terminal PD1⁺ CD8⁺ T cells and an increase in active terminal PD1⁺ CD8⁺ T cells (22).

In China, 82 patients with stage III and IV cancer were prospectively followed-up, after treatment with H₂ inhalation. No severe hematological toxicity was observed. H₂ Inhalation of H₂ gas induced complete and partial remission in tumors of the 80 patients at 21–80 days (median 55 days). In patients with advanced cancer, inhaled H₂ can improve patients' quality-of-life and control cancer progression (23,24).

Inhalation of H₂ gas may be a simple and low-cost treatment with no or little adverse effect, and will require further investigation as a strategy to cure or improve patients with advanced cancer.

Concluding remarks

H₂ has strong potential for actual applications in various medical fields, including ischemia-reperfusion injury, advanced stage cancer, dementia, and metabolic syndrome. H₂ should be very unusual from the viewpoint of conventional medicine because of its absence of cytotoxicity and its multiple functions to overcome severe diseases from chronic to acute stages. Thus, to receive public approval is critical for the application of the H₂ treatment.

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: The author holds a right of patents involved in H₂ therapy for ischemia-reperfusion injury.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. *Nat Med* 2011;17:1391-401.
- Malý O, Zajak J, Hyšpler R, et al. Inhalation of molecular hydrogen prevents ischemia-reperfusion liver damage during major liver resection. *Ann Transl Med* 2019;7:774.
- Ohta S. Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. *Pharmacol Ther* 2014;144:1-11.
- Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med* 2007;13:688-94.
- Kamimura N, Nishimaki K, Ohsawa I, et al. Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice. *Obesity (Silver Spring)* 2011;19:1396-403.
- Cole AR, Raza A, Ahmed H, et al. Safety of inhaled hydrogen gas in healthy mice. *Med Gas Res* 2019;9:133-8.
- Fontanari P, Badier M, Guillot C, et al. Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive. *Eur J Appl Physiol* 2000;81:325-8.
- Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. *Biochem Biophys Res Commun* 2008;373:30-5.
- Cai J, Kang Z, Liu K, et al. Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. *Brain Res* 2009;1256:129-37.
- Oharazawa H, Igarashi T, Yokota T, et al. Protection of the retina by rapid diffusion of hydrogen: administration of hydrogen-loaded eye drops in retinal ischemia-reperfusion injury. *Invest Ophthalmol Vis Sci* 2010;51:487-92.
- Noda K, Shigemura N, Tanaka Y, et al. A novel method of preserving cardiac grafts using a hydrogen-rich water bath. *J Heart Lung Transplant* 2013;32:241-50.
- Yoshida A, Asanuma H, Sasaki H, et al. H mediates cardioprotection via involvements of K(ATP) channels and permeability transition pores of mitochondria in dogs. *Cardiovasc Drugs Ther* 2012;26:217-26.
- Hayashida K, Sano M, Kamimura N, et al. Hydrogen Inhalation During Normoxic Resuscitation Improves Neurological Outcome in a Rat Model of Cardiac Arrest, Independent of Targeted Temperature Management. *Circulation* 2014;130:2173-80.
- Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. *Am J Transplant* 2008;8:2015-24.
- Cole AR, Perry DA, Raza A, et al. Perioperatively Inhaled Hydrogen Gas Diminishes Neurologic Injury Following Experimental Circulatory Arrest in Swine. *JACC Basic Transl Sci* 2019;4:176-87.
- Ono H, Nishijima Y, Ohta S, et al. Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection. *J Stroke Cerebrovasc Dis* 2017;26:2587-94.
- Katsumata Y, Sano F, Abe T, et al. The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction- First Pilot Study in Humans. *Circ J* 2017;81:940-7.
- Tamura T, Hayashida K, Sano M, et al. Feasibility and Safety of Hydrogen Gas Inhalation for Post-Cardiac Arrest Syndrome- First-in-Human Pilot Study. *Circ J* 2016;80:1870-3.
- Tamura T, Hayashida K, Sano M, et al. Efficacy of inhaled H₂ on neurological outcome following Brain Ischemia During post-cardiac arrest care (HYBRID II trial): study protocol for a randomized controlled trial.

- Trials 2017;18:488.
20. Iuchi K, Imoto A, Kamimura N, et al. Molecular hydrogen regulates gene expression by modifying the free radical chain reaction-dependent generation of oxidized phospholipid mediators. *Sci Rep* 2016;6:18971.
 21. Kamimura N, Ichimiya H, Iuchi K, et al. Molecular hydrogen stimulates the gene expression of transcriptional coactivator PGC-1 α to enhance fatty acid metabolism. *NPJ Aging Mech Dis* 2016;2:16008.
 22. Akagi J, Baba H. Hydrogen gas restores exhausted CD8⁺ T cells in patients with advanced colorectal cancer to improve prognosis. *Oncol Rep* 2019;41:301-11.
 23. Chen JB, Pan ZB, Du DM, et al. Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. *World J Clin Cases* 2019;7:2065-74.
 24. Chen JB, Kong XF, Lv YY, et al. "Real world survey" of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients. *Med Gas Res* 2019;9:115-21.

Cite this article as: Ohta S. Will the hydrogen therapy be approved shortly? *Ann Transl Med* 2020;8(6):264. doi: 10.21037/atm.2020.03.70